The infusion of TIL586 along with interleukin-2 (IL-2) into the autologous patient with metastatic melanoma resulted in the objective regression of tumor. A gene encoding a tumor antigen recognized by TIL586 was previously isolated and shown to encode gp75 or TRP-1. The present invention relates to the identification of a second tumor antigen recognized by a HLA-A31 restricted CTL clone derived from the TIL586 cell line. This antigen derived from the TRP-2 protein tumor antigen and peptides thereof are capable of sensitizing target cells for lysis by a CTL clone at 1 nM peptide concentration. Modified peptides were also recognized by the CTL clone.
This application is a divisional of 09/161,877 filed Sep. 28, 1998 U.S. Pat. No. 6,132,980; which is a divisional of 09/162,368 filed Sep. 28, 1998 U.S. Pat. No. 6,083,703; which is a divisional of 08/725,736 filed Oct. 4, 1996 U.S. Pat. No. 5,831,016, which is a CIP of 08/599,602 Feb. 9, 1996 Pat. 5,840,839.
